Skip to contentN
Nutra Pharma Corp
N
NPHCNutra Pharma Corp Q1 2026 · 10-Q
Revenue$27.25K$27.25K−63.2% vs Q1 2025 Net Income-$459.68K-$459.68KN/M vs Q1 2025 EPS Diluted$0.00$0.00— vs Q1 2025 Gross Profit$18,975−72.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nutra Pharma Corp · CIK 1119643 · Engraved from SEC EDGAR
Operating Cash Flow-$327,791N/M Margins · derivedGross margin69.6%−22.7 pt vs Q1 2025
Operating margin-1391.9%−919.0 pt vs Q1 2025
Net margin-1687.1%+212.1 pt vs Q1 2025
ended Mar 31, 2026 · filed May 29, 2026 · 59 d after period end